NPI: 1104903749 · HUEYTOWN, AL 35023 · Pediatrics Physician · NPI assigned 11/01/2006
Authorized official WALTON, DAWN controls 19+ related entities in our dataset. Read more
| Authorized Official | WALTON, DAWN (CFO) |
| Parent Organization | THE CHILDREN'S HOSPITAL OF ALABAMA |
| NPI Enumeration Date | 11/01/2006 |
Other providers sharing the same authorized official: WALTON, DAWN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 54,292 | $2.99M |
| 2019 | 64,859 | $2.74M |
| 2020 | 55,745 | $2.26M |
| 2021 | 80,987 | $3.44M |
| 2022 | 90,522 | $3.86M |
| 2023 | 87,912 | $3.54M |
| 2024 | 83,979 | $3.40M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 67,988 | 62,875 | $6.60M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 87,212 | 80,173 | $5.49M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 19,486 | 19,153 | $1.38M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 18,209 | 17,696 | $1.27M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 15,535 | 15,174 | $1.07M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 22,406 | 21,341 | $916K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 9,922 | 9,713 | $693K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 13,193 | 12,703 | $600K |
| 87428 | 13,335 | 12,616 | $586K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 35,334 | 33,710 | $445K |
| 90698 | 15,678 | 15,451 | $390K | |
| 90670 | 11,424 | 11,258 | $361K | |
| 87634 | 5,611 | 5,357 | $257K | |
| 90686 | 11,726 | 11,519 | $225K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3,756 | 3,682 | $209K |
| 90680 | 8,272 | 8,156 | $184K | |
| 99173 | 33,862 | 32,893 | $160K | |
| 90461 | 2,155 | 2,135 | $140K | |
| 92551 | 26,368 | 25,602 | $125K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4,750 | 4,550 | $100K |
| 90633 | 4,922 | 4,836 | $96K | |
| 90744 | 4,759 | 4,666 | $91K | |
| 90651 | 2,962 | 2,857 | $81K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8,533 | 8,190 | $79K |
| 90677 | 2,172 | 2,144 | $79K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 5,648 | 5,568 | $63K |
| 90671 | 1,817 | 1,791 | $53K | |
| 96127 | 15,003 | 14,652 | $50K | |
| 90734 | 1,738 | 1,677 | $44K | |
| 83655 | 2,464 | 2,423 | $34K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 967 | 892 | $30K |
| 90619 | 1,199 | 1,158 | $29K | |
| 99000 | 8,693 | 8,306 | $28K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 479 | 470 | $26K |
| 94664 | 1,965 | 1,856 | $20K | |
| 81003 | 6,697 | 6,314 | $18K | |
| 90710 | 710 | 695 | $16K | |
| 90656 | 842 | 838 | $16K | |
| 36416 | 8,530 | 7,811 | $16K | |
| 96161 | 5,433 | 5,286 | $15K | |
| 90715 | 788 | 757 | $14K | |
| 90696 | 722 | 705 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 525 | 510 | $13K |
| 90716 | 433 | 427 | $9K | |
| 99215 | Prolong outpt/office vis | 102 | 93 | $9K |
| 90707 | 436 | 430 | $9K | |
| 0071A | 232 | 217 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 470 | 440 | $8K |
| 99461 | 67 | 66 | $6K | |
| 0072A | 127 | 124 | $5K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 47 | 44 | $4K |
| 36415 | Collection of venous blood by venipuncture | 1,409 | 1,315 | $3K |
| 69210 | 49 | 28 | $3K | |
| D0145 | Oral evaluation for a patient under three years of age | 172 | 167 | $3K |
| 90685 | 118 | 118 | $2K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 31 | 28 | $2K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 12 | 12 | $2K |
| D1206 | Topical application of fluoride varnish | 90 | 89 | $2K |
| 80061 | Lipid panel | 98 | 93 | $1K |
| 90620 | 51 | 50 | $969.71 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 39 | 39 | $741.00 |
| 92567 | 28 | 26 | $392.00 | |
| 99051 | 14 | 14 | $371.86 | |
| 82247 | 75 | 55 | $335.00 | |
| 90700 | 13 | 13 | $257.27 | |
| 90648 | 12 | 12 | $237.48 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 13 | 13 | $213.46 |
| 99177 | 13 | 13 | $181.32 | |
| 86308 | 12 | 12 | $72.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 13 | 13 | $26.90 |
| 99080 | 316 | 303 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 14 | 13 | $0.00 |